No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	obecabtagene autoleucel Sensitive: A1 - Approval FDA - 1 week (New A1) obecabtagene autoleucel Sensitive : A1 FDA - 1wk	obecabtagene autoleucel Sensitive: A1 - Approval FDA - 1 week obecabtagene autoleucel Sensitive : A1 FDA - 1 week - (New A1)
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1	dasatinib Sensitive: A1 - Approval dasatinib Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
CD20 positive	Childhood B Acute Lymphoblastic Leukemia	CD20 positive	Childhood B Acute Lymphoblastic Leukemia	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	calaspargase pegol-mknl Sensitive: A1 - Approval calaspargase pegol-mknl Sensitive : A1	calaspargase pegol-mknl Sensitive: A1 - Approval calaspargase pegol-mknl Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	calaspargase pegol-mknl Sensitive: A1 - Approval calaspargase pegol-mknl Sensitive : A1	calaspargase pegol-mknl Sensitive: A1 - Approval calaspargase pegol-mknl Sensitive : A1
ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	ABL2 fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
IL7R mutation	Childhood B Acute Lymphoblastic Leukemia	IL7R mutation	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
SH2B3 alteration	Childhood B Acute Lymphoblastic Leukemia	SH2B3 alteration	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
EPOR rearrangement	Childhood B Acute Lymphoblastic Leukemia	EPOR rearrangement	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
ABL1 fusion	Childhood B Acute Lymphoblastic Leukemia	ABL1 fusion	Childhood B Acute Lymphoblastic Leukemia	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2	dasatinib Sensitive: A2 - Guideline dasatinib Sensitive : A2
JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive : A2	vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + nelarabine Sensitive : A2	cyclophosphamide + etoposide oral + nelarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + nelarabine Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2	cyclophosphamide + etoposide oral + clofarabine Sensitive: A2 - Guideline cyclophosphamide + etoposide oral + clofarabine Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2	Tyrosine kinase inhibitor Sensitive: A2 - Guideline Tyrosine kinase inhibitor Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2	bosutinib Sensitive: A2 - Guideline bosutinib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2	ponatinib Sensitive: A2 - Guideline ponatinib Sensitive : A2

B Acute Lymphoblastic Leukemia

Associations(193)

Associations
(193)